Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Randomised Controlled ◽

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(13)61094-6 ◽

2013 ◽

Vol 382 (9897) ◽

pp. 1021-1028 ◽

Cited By ~ 305

Author(s):

Aron Goldhirsch ◽

Richard D Gelber ◽

Martine J Piccart-Gebhart ◽

Evandro de Azambuja ◽

Marion Procter ◽

...

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Randomised Controlled ◽

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(07)60028-2 ◽

2007 ◽

Vol 369 (9555) ◽

pp. 29-36 ◽

Cited By ~ 1033

Author(s):

Ian Smith ◽

Marion Procter ◽

Richard D Gelber ◽

Sébastien Guillaume ◽

Andrea Feyereislova ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Her2 Positive ◽

Randomised Controlled ◽

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial

Oncotarget ◽

10.18632/oncotarget.21579 ◽

2017 ◽

Vol 8 (54) ◽

pp. 92778-92787 ◽

Cited By ~ 1

Author(s):

Songjie Shen ◽

Ying Xu ◽

Yidong Zhou ◽

Feng Mao ◽

Jinghong Guan ◽

...

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Her2 Positive ◽

Concurrent Administration ◽

Randomised Controlled ◽

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

Annals of Oncology ◽

10.1093/annonc/mdw055 ◽

2016 ◽

Vol 27 (5) ◽

pp. 806-812 ◽

Cited By ~ 8

Author(s):

N. Zdenkowski ◽

J.F. Forbes ◽

F.M. Boyle ◽

G. Kannourakis ◽

P.G. Gill ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Adjuvant Endocrine Therapy ◽

Open Label ◽

Hormone Receptor Positive ◽

Randomised Controlled ◽

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61523-3 ◽

2009 ◽

Vol 374 (9707) ◽

pp. 2055-2063 ◽

Cited By ~ 163

Author(s):

Kathy S Albain ◽

William E Barlow ◽

Peter M Ravdin ◽

William B Farrar ◽

Gary V Burton ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79516-6 ◽

2010 ◽

Vol 2010 ◽

pp. 19-21

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽

Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969433.793480577 ◽

2013 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Phase 3 ◽

Randomised Controlled ◽

Adjuvant Trastuzumab in HER2-Positive Breast Cancer: Observational Monocentric Study of 84 Cases

Annals of Oncology ◽

10.1093/annonc/mdt079.3 ◽

2013 ◽

Vol 24 ◽

pp. iii16

Author(s):

M. Aitelhaj ◽

S. Lkhoyaali ◽

G. Rais ◽

A. Mohtaram ◽

S. Boutayeb ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30088-8 ◽

2017 ◽

Vol 18 (3) ◽

pp. 371-383 ◽

Cited By ~ 21

Author(s):

Pin Zhang ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Heavily Pretreated ◽

Randomised Controlled

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30570-9 ◽

2018 ◽

Vol 19 (12) ◽

pp. 1630-1640 ◽

Cited By ~ 34

Author(s):

Mette S van Ramshorst ◽

Anna van der Voort ◽

Erik D van Werkhoven ◽

Ingrid A Mandjes ◽

Inge Kemper ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽